Condition: Age-related Macular Degeneration (AMD) · Sponsor: Centre Hospitalier Universitaire, Amiens
Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.
This description comes directly from the study's public registry record.
Sophie BRYSELBOUT, Dr · 33 3 22 08 92 19 · bryselbout.sophie@chu-amiens.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens | Amiens, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03577041